Detection of sexually transmitted pathogens and co-infection with human papillomavirus in women residing in rural Eastern Cape, South Africa

Ongeziwe Taku¹,², Adrian Brink³, Tracy L. Meiring¹,², Keletso Phohlo¹,², Charles B. Businge⁴,⁵, Zizipho Z.A. Mbulawa¹,⁶,⁷,⁸ and Anna-Lise Williamson¹,²,⁶

¹ Department of Pathology, Faculty of health sciences, University of Cape Town, Cape Town, South Africa
² Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, Western Cape, South Africa
³ Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
⁴ Department of Obstetrics and Gynaecology, Nelson Mandela Academic Hospital, Mthatha, South Africa
⁵ Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa
⁶ SAMRC Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa
⁷ Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha, South Africa
⁸ National Health Laboratory Service, Nelson Mandela Academic Hospital, Mthatha, South Africa

ABSTRACT

Background. South African women of reproductive age have a high burden of sexually transmitted infections (STIs), including human papillomavirus (HPV) infection. However, there is limited information on the prevalence of sexually transmitted pathogens in women from rural Eastern Cape Province, South Africa. The study aims at determining the prevalence of sexually transmitted pathogens and co-infection with high-risk (HR) HPV among women from rural Eastern Cape Province, South Africa.

Methods. A total of 205 cervical specimens were collected from women aged ≥30 years from a rural community-based clinic. The samples were tested for a panel of pathogenic STIs [Chlamydia trachomatis (serovars A-K & L1-L3), Haemophilus ducreyi, Herpes Simplex Virus (Types 1 & 2), Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis (TV), and pathobionts [Mycoplasma genitalium (MG), Mycoplasma hominis (MH) and Ureaplasma spp. (UP)]] using a multiplex PCR STD direct flow chip assay through a manual Hybrispot platform (Master Diagnostica, Granada, Spain). HR-HPV detection was performed by Hybrid Capture-2 assay.

Results. High-risk HPV prevalence was 32.2% (66/205) and HIV-1 prevalence was 38.5% (79/205). The overall prevalence of six pathogenic STIs was 22.9% (47/205), with TV having the highest prevalence (15.6%; 32/205). UP (70.2%, 144/205) and MH (36.6%, 75/205) were the most frequently detected pathobionts. Co-infection with ≥2 pathogens pathobionts was observed among 52.7% (108/205) participants. Of the six pathogenic STIs, three participants had more than one STI (1.46%) with the presence of MH and UP. HSV-2 (OR: 4.17, CI [1.184–14.690]) and HIV infection (OR: 2.11, CI [1.145–3.873]) were independent STIs associated with HR-HPV infection.

Conclusions. The high prevalence of pathogenic STIs underscores the need to improve syndromic management policy by implementing effective strategies of prevention,
screening tests, and management. HSV-2 and HIV positive remain strongly associated with HR-HPV infection.

**Subjects** Molecular Biology, Infectious Diseases, Women’s Health  
**Keywords** HPV, Sexually transmitted pathogens, *Treponema pallidum*, *Trichomonas Vaginalis*, *Mycoplasma genitalium*, *Mycoplasma hominis*, Ureaplasma

**INTRODUCTION**

Internationally, sexually transmitted infections (STIs) are a significant public health problem, with an estimated more than one million people infected each day. According to the World Health Organization, the global estimate of new infections with commonly treatable STIs [*Trichomonas vaginalis* (TV), *Treponema pallidum* (TP), *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG)] was 376.4 million in 2016 (*WHO, 2018*). Africa accounts for 69 million new infections of treatable STIs with women having a high burden of *TV* (11, 8%) and *CT* (5, 0%) (*WHO, 2018*). STIs have an impact on women’s health, associated with cervicitis, urethritis, pelvic inflammation, complications of reproductive health, and poor pregnancy outcomes (*Mermelstein & Plax, 2016*). South African women have a high prevalence of STIs, ranging from 12.7% to 47.8%, which differs by age, region, and population (*Joseph Davey et al., 2019; Moodley et al., 2015; Mudau et al., 2018; Naidoo et al., 2014*). The burden of STIs is more common among women of reproductive age (15–49 years) (*WHO, 2018*). The acquisition of new STIs occurs at all ages, and high rates of STIs are more likely to be found in younger women (*Naidoo et al., 2014*). In South African studies, women age <25 years are almost 2-fold more likely to have STIs compared to older women (>25 years) and have high rates of co-infections (*Mbululwa et al., 2018; Menezes et al., 2018; Naidoo et al., 2014*).

Human papillomavirus (HPV) is the most common and infectious viral STI, with 291 million new infections estimated to have occurred in 2016, with a particularly high burden among women in Southern Africa (*Bruni et al., 2010; WHO, 2018*). Most HPV infections are transient, but 5% remain persistent and can progress to high-grade lesions or cervical cancer (*Schiffman et al., 2011*). The high burden of HPV infection is influenced by several factors, including co-infection with other STIs. HIV infection is a significant independent factor of HPV, and infection with either HPV or HIV is thought to enhance the spread of the other infection (*Smith-McCune et al., 2010*). HIV-positive women have been reported to have a higher prevalence and higher viral load of high-risk (HR) HPV compared to HIV-negative women (*Taku et al., 2020*). In addition, *CT*, Herpes Simplex Virus-2 (HSV-2), and NG increase the risk of HIV acquisition (*Adachi et al., 2015; Johnson & Lewis, 2008; Looker et al., 2017*). These STIs are co-factors of HPV and may have an impact on the natural history of HPV (*Deluca et al., 2011; De Abreu et al., 2016; Paba et al., 2008; Smith et al., 2002a; Smith et al., 2002b*). The association of HPV infection with some of these STIs is due to chronic inflammation or immunosuppression, which promotes the susceptibility to and progression of HR-HPV persistent infection (*Adefuye & Sales, 2012; Denny et al., 2012; Liu et al., 2016; Paba et al., 2008; Silins et al., 2005*). HPV-positive women co-infected with
one or more of these STIs are at high risk of developing cervical cancer diseases and invasive cervical cancer (Deluca et al., 2011; Paba et al., 2008; Smith et al., 2002a). Consequently, women harbouring or having a history of CT are less likely to clear HPV infection, and two times more likely to develop cervical cancer diseases (Jensen et al., 2014; Lehtinen et al., 2011; Vriend et al., 2015). Moreover, sexually transmitted pathobionts such as Mycoplasma hominis (MH) and Ureaplasma spp. (UP) are associated with an increased risk of HPV persistent infection and abnormal cervical cytology (Parthenis et al., 2018). Therefore, it is crucial to screen for these sexually transmitted pathogens to reduce the risk of transmission and their outcome.

In South Africa, the current strategy for diagnosing STIs is through clinical indicators such as vaginal discharge, pelvic pain, and ulcerative genital lesions (Health NDo, 2015). The syndromic management approach has been successful in treating many pathogens causing STIs and reducing the burden of other STIs such as TP (Kularatne et al., 2018). However, this approach may result in overtreatment, antimicrobial resistance, and is not effective in people with STIs who do not show any clinical symptoms (Mayaud & Mabey, 2004). South African studies reported a high prevalence of asymptomatic women, ranging from 50–75%, harbouring genital tract infections (Francis et al., 2018; Wilkinson et al., 1999). Since many STIs are asymptomatic and missed by the syndromic management approach, laboratory-based diagnosis remains the only strategy that allows the detection of genital tract infections (Sznitman et al., 2010).

Moreover, screening programmes allow people to be informed about STIs, which helps to prevent and manage the spread of STIs (Sznitman et al., 2010). Women residing in rural areas have limited knowledge of STIs and not likely to be informed about STIs services due to lack of access to healthcare facilities or facilities having limited resources to treat STIs (Cristillo et al., 2017; Wi et al., 2019). There is limited information on STIs and the prevalence of specific sexually transmitted pathogens in Eastern Cape Province. Therefore, the study aims at investigating the prevalence of sexually transmitted pathogens in women from rural Eastern Cape using molecular detection.

**MATERIALS AND METHODS**

Cohort description or description of study participants: Two hundred and five cervical samples were selected from a cross-sectional study done between September 2017 and August 2018. The cross-sectional study has been described in detail previously (Taku et al., 2020). Briefly, women aged 30 years or more attending cervical cancer screenings or for other reasons were recruited from a community-based clinic within the OR Tambo District, Eastern Cape. All signed consent forms were obtained from all enrolled women. Women were requested to test for HIV if they were not aware of their HIV status or if their HIV status was not documented on their health card. Women received pre-HIV testing counselling prior to and after testing them for HIV using a rapid test (Alere Determine™ HIV-1/2 Ag/Ab Combo, Alere, Waltham, MA). The protocol of this study was approved by the Human Research Ethics Committees of the University of Cape Town (UCT) (HREC reference 615/2017), Walter Sisulu University (reference 016/2017), and Eastern Cape
Department of Health Ethics (EC reference 2017RP0_484). Cervical specimens were stored in the Digene Specimen Transport Medium (Qiagen, Inc., Gaithersburg, MD; USA), transported to UCT, and kept at \(-80^\circ\text{C}\) until further analysis.

There was no special selection criteria considered for this study. The median age of the women was 45 years (IQR: 38-53), and the median number of lifetime sexual partners was three. A total of 61.5% (126/205) of the women reported not using a condom during their last sexual encounter. More than half of women (58.5%, 120/205) reported not using any method of contraception with their current partner. One hundred and ten (110) study participants (53.6%) reported having had vaginal discharge with 44.5% (49/110) reporting to have occurred more or equal to six months (Table 1). 38.5% (79/205) women were positive for HIV and 96.2% (76/79) were on antiretroviral drugs. The majority of women (88.8%, 182/205 ) had normal cervical cytology while , 7.8% (16/205) were positive for ASCUS, 2.0% (4/205) for low grade intraepithelial squamous lesions and 1.0% (2/205) for high grade squamous intraepithelial lesions. One participant had had an inadequate result (0.5%,1/205).

**DNA extraction**
The DNA was extracted from each cervical specimen (400 µl) using the MagNA Pure Compact Nucleic Acid Isolation kit (Roche Diagnostic, Mannheim, Germany) on an automated Roche MagNA Pure Compact system. DNA was eluted in 100 µl elution buffer and stored at \(-20^\circ\text{C}\) until further use.

**Detection of sexually transmitted pathogens**
Extracted DNA was used for detection of STD performed using multiplex PCR STD direct flow chip assay through a manual Hybrispot platform (Master Diagnostica, Granada, Spain) following the manufacturer’s instructions. The panel detects the following pathogens: TP, HSV (Type 1 & 2), TV, CT (Biovary LGV: Serovars L1-L3 & Serovars A-K), NG, *Haemophilus ducreyi* as well as UP (urealyticum/parvum), MG and MH (*Barrientos-Durán et al., 2020*).

The image results of each chip membrane were captured by a camera, and analysis was performed automatically with HybriSoft software.

**Detection of HR-HPV infection**
Cervical specimens in Digene transport medium were tested for 13 HR-HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) using the Hybrid Capture-2 (HC-2) assay (Qiagen, Inc., Gaithersburg, MD; USA) according to the manufacturer’s protocol. A ratio of relative light units/cut-off \(\geq 1\) was considered positive, while a ratio of < 1 was considered negative for HR-HPV types.

**Data analysis**
Single infection was defined as being positive for one of any pathogenic STIs or pathobionts. Multiple infections was defined as having two or more microorganisms (pathogenic STIs/pathobionts). Statistical analysis was performed using STATA 15.0 (STATA Corp, College Station, TX, USA). Univariate logistic regression models were conducted to determine the association between sexually transmitted pathogens and HR-HPV infection.
Table 1  Description of the study participants.

| Variables                                      | % (n/N)  |
|------------------------------------------------|----------|
| Age in years, median (IQR)                     | 45 (38–53) |
| **Age category**                               |          |
| 30–39 years                                    | 33.7% (69/205)  |
| 40–49 years                                    | 28.8% (59/205)  |
| ≥50 years                                      | 37.6% (77/205)  |
| **Lifetime partners**                          |          |
| 1                                              | 15.1% (31/205)  |
| 2                                              | 29.8% (61/205)  |
| ≥3                                             | 55.1% (113/205) |
| **Sexual partners past 12 months**             |          |
| 0                                              | 26.3% (54/205)  |
| ≥1                                             | 73.7% (151/205) |
| **Sexual partners past 1 month**               |          |
| 0                                              | 41.5% (85/205)  |
| ≥1                                             | 58.5% (120/205) |
| **Vaginal sexual intercourse**                 |          |
| 0                                              | 49.3% (101/205) |
| 1–3                                            | 33.2% (68/205)  |
| ≥4                                             | 17.1% (35/205)  |
| **Condom use**                                 |          |
| No                                             | 61.5% (126/205) |
| Yes                                            | 37.1% (76/205)  |
| **Discharge**                                  |          |
| No                                             | 46.3% (95/205)  |
| Yes                                            | 53.7% (110/205) |
| **Frequency of vaginal discharge**             |          |
| Current/last week                              | 18.1% (37/205)  |
| More than a week and less than 6 months        | 11.2% (23/205)  |
| More than or equal to 6 months                 | 23.9% (49/205)  |
| **Using any contraception with current partner**|          |
| No                                             | 58.5% (120/205) |
| Yes                                            | 40.0% (82/205)  |
| **Pregnancy**                                  |          |
| No                                             | 4.4% (9/205)    |
| Yes                                            | 95.6% (196/205) |
| **HIV infection**                              |          |
| Negative                                       | 61.5% (126/205) |
| Positive                                       | 38.5% (79/205)  |

Multivariate analysis was done using the statistically significant variables (p-value < 0.05) of the univariate logistic regression models to identify the sexually transmitted pathogens that are independently associated with HR-HPV infection.
Table 2  Prevalence of sexually transmitted infections detected using multiplex PCR STD direct flow
chip assay.

| Variables                              | % (n/N)   |
|----------------------------------------|-----------|
| Chlamydia trachomatis (serovars L1-L3) | 0.5% (1/205) |
| Chlamydia trachomatis (serotypes A-K)  | 2.0% (4/205) |
| Herpes simplex virus Types I           | 0.0% (0/205) |
| Herpes simplex virus Types II          | 5.9% (12/205) |
| Trichomonas vaginalis                  | 15.6% (32/205) |
| Neisseria gonorrhoeae                  | 1.5% (3/205) |
| Treponema pallidum                     | 0.0% (0/205) |
| Haemophilus ducreyi                    | 0.0% (0/205) |
| Mycoplasma hominis                     | 36.6% (75/205) |
| Ureaplasmas (U. urealyticum or U. parvum)| 70.2% (144/205) |
| Mycoplasma genitalium                  | 1.5% (3/205) |

RESULTS

Sexually transmitted pathogens / pathobionts and pattern of infection

HR-HPV prevalence was 32.2% (66/205) and HIV-1 prevalence was 38.5% (79/205). The overall prevalence of the six STIs was 22.9% (47/205) with a highest number of women positive for TV (15.6%, 32/205) followed by HSV-2 (5.9%, 12/205), CT (2.4%, 5/205) and NG (1.5%, 3/205) (Table 2). Of the pathobionts, UP (70.2%, 144/205) and MH (36.6%, 75/205) were the most frequently detected (Table 2). Overall, the prevalence of single infection was 31.2% (64/205), with most women infected with UP (62.5%) and HR-HPV infection (17.2%) (Figs. 1A, 1B and 1C). Furthermore, multiple infections were found in 52.7% (108/205) women, with 30.7% had dual infection (2 pathogens / pathobionts) and 22.0% co-infected with more than three pathogens / pathobionts (Figs. 1B, 1C and 1D). A higher proportion of co-infection was observed among women with UP, whereby UP/MH (26.9%), UP/HPV (21.3%), and MH/UP/TV (10.2%) were the most commonly detected co-infections (Figs. 1C and 1D). Of the six pathogenic STIs, three participants had more than one STI (1.46%) with the presence of MH and UP. Women with HSV-2 infection were almost five times more likely to be infected with HR-HPV (OR: 4.65, CI [1.35–16.071]). In the multivariate analysis, HSV-2 (OR: 4.17, CI [1.184–14.690]) and HIV infection (OR: 2.11, CI [1.145–3.873]) remained the significant risk factors of HR-HPV infection (Table 3).

Of the women with self-reported vaginal discharge, a total of 21 (19.1%) were positive for treatable STIs, including 56.3% (18/32) with TV and 60.0% (3/5) with CT (refer to supplementary data). All women positive for NG self-reported not having had vaginal discharge (100.0%, 3/3). Similarly, the pelvic examination done by the study nurse showed that 28.1% (9/32) of women positive for TV had vaginal discharge but none of the women positive for NG had vaginal discharge. The association of STIs and behavioural factors are depicted in Table S1. Women having 3 or more lifetime sexual partners was associated with STIs (OR: 3.69, CI [1.047–12.986], P = 0.042). In addition, women age ≥50 years (OR:0.38, CI [0.185–0.797], P = 0.010) or reported having had vaginal discharge for more
than or equal to six months (OR:0.38, CI [0.149–0.967], \( P = 0.042 \)) had a lower risk of HPV infections whereas three or more lifetime sexual partners (OR:3.08, CI [1.098–8.619], \( P = 0.033 \)), HIV positive (OR:2.22, CI [1.219–4.042], \( P = 0.009 \)) were significant risk factors of increased HR-HPV infection (Table S2). However, in the multivariate analysis none of these factors remained a significant risk factor of HR-HPV infection (Table S2).

**DISCUSSION**

We investigated the prevalence of sexually transmitted pathogens/pathobionts and co-infection with HPV infection among women from rural Eastern Cape. The study demonstrates a high overall prevalence of the conventional pathogenic STIs (22.9%) and confirms the high prevalence of TV (15.6%) in this population. The high burden of TV has been previously reported in South African women of a rural region, occurring in 66% of asymptomatic women (De Waaij et al., 2017). It has been found that hormonal changes and menstrual bleeding contribute to the increase of TV and put women at high risk of being more susceptible to acquisition and persistent infection (Poole & McClelland, 2013). Women with TV persistence have an increased risk of acquiring HIV, a high viral load of HIV, and a likelihood of transmitting HIV infection to their sexual partners (De Waaij et al., 2017; Van der Pol, 2007). Also, the high prevalence of TV may cause serious reproductive health problems in this group of women, as shown in previous studies (Kissingner, 2015).
Table 3  Association of sexually transmitted pathogens and HR-HPV infection.

| Variables                              | HR-HPV prevalence | Univariate analysis | Multivariate analysis |
|----------------------------------------|-------------------|---------------------|-----------------------|
|                                        | % (n/N)           | OR (95% CI)         | P-value               |
|                                        |                   |                     |                       |
| **Mycoplasma hominis**                  |                   |                     |                       |
| Negative                               | 33.9% (44/130)    | Ref                 |                       |
| Positive                               | 29.3% (22/75)     | 0.81 (0.438–1.502)  | 0.506                 |
| **Ureaplasmas species**                 |                   |                     |                       |
| (U. urealyticum or U. parvum)          |                   |                     |                       |
| Negative                               | 24.6% (15/61)     | Ref                 |                       |
| Positive                               | 35.4% (51/144)    | 1.68 (0.856–3.305)  | 0.131                 |
| **Trichomonas Vaginalis**               |                   |                     |                       |
| Negative                               | 31.8% (55/173)    | Ref                 |                       |
| Positive                               | 34.4% (11/32)     | 1.12 (0.507–2.493)  | 0.838                 |
| **Herpes Simplex Virus Types II**       |                   |                     |                       |
| Negative                               | 30.1% (58/193)    | Ref                 |                       |
| Positive                               | 66.7% (8/12)      | 4.65 (1.35–16.071)  | **0.015**             |
| **Chlamydia Trachomatis**              |                   |                     |                       |
| (serovars L1-L3 & A-K)                 |                   |                     |                       |
| Negative                               | 32.5% (65/200)    | Ref                 |                       |
| Positive                               | 20.0% (1/5)       | 0.52 (0.057–4.739)  | 0.561                 |
| **Neisseria gonorrhoeae**               |                   |                     |                       |
| Negative                               | 32.2% (65/202)    | Ref                 |                       |
| Positive                               | 33.3% (1/3)       | 1.05 (0.094–11.834) | 0.966                 |
| **Mycoplasma genitalium**               |                   |                     |                       |
| Negative                               | 31.7% (64/202)    | Ref                 |                       |
| Positive                               | 66.7% (2/3)       | 4.31 (0.384–48.434) | 0.236                 |
| **HIV infection**                      |                   |                     |                       |
| Negative                               | 25.4% (32/126)    | Ref                 |                       |
| Positive                               | 43.0% (34/79)     | 2.22 (1.219–4.042)  | **0.009**             |

Notes. HR-HPV, high-risk human papillomavirus; OR, odds ratio; CI, confidence intervals; ref, reference, Highlighted values; significant p-value.

Therefore, better screening programmes and control measures to reduce the burden of this STI are of critical importance, particularly among asymptomatic women. The positivity rate for CT (2.4%) and NG (1.5%) was low in this cohort and similar to that observed in community-based studies conducted among older women from rural and urban regions of sub-Saharan Africa (Dubbink et al., 2018). The highest rates of CT/NG are usually observed among younger women (<25 years) because of biological vulnerability (such as immature ectopic tissue on the cervix) and sexual behaviour which makes them prone to the growth of these pathogens (Lee, Tobin & Foley, 2006; Menezes et al., 2018). For example, amongst asymptomatic young HIV-negative South African women (<25 years), high rates of 33.5% and 11.1%, have been recorded for CT and NG, respectively (Menezes et al., 2018). Sexual behaviour was a significant risk factor, suggesting that more campaigns are needed to educate younger women and men about sexual and reproductive health (Menezes et al., 2018).
Notably, a high prevalence of UP (70.2%) and MH (36.6%) was observed, occurring in multiple infections. UP and MH are emerging pathobionts found in women both with healthy and unhealthy vaginal microbiota (Cox et al., 2016; Rumyantseva et al., 2019; Waites, Katz & Schelonka, 2005). The prevalence of UP is between 40–80%, while MH ranges between 21–53% in cervical/vaginal specimens of sexually active women (Cox et al., 2016; Waites, Katz & Schelonka, 2005). Previous studies have reported an association of these pathogens with bacterial vaginosis (BV) and STI, such as MG, and CT (Marovt et al., 2015). Rumyantseva and colleagues (2019) reported a significantly higher prevalence of UP (73.4%) among women with BV compared to women with normal bacterial flora (49.4%) or aerobic vaginitis (28.4%) (Rumyantseva et al., 2019). MH is considered BV-associated bacteria and has been reported to have a significantly higher bacterial load in women with BV compared to women without BV (Rumyantseva et al., 2019; Sha et al., 2005). Women with BV are reported to have high vaginal pH (>4.5) which is a favourable vaginal environment for pathogenic organisms (Kaambo et al., 2018). Additionally, women with detectable MH were often found to be co-infected with Gardnerella vaginalis, and such co-infection has been demonstrated in 60.7% of BV-positive women compared to BV-negative women (8.8%), which demonstrate a possible interaction between these pathogens (Cox et al., 2016). The transmission of either MH or Gardnerella vaginalis could activate the growth of the other, which may promote or contribute to the progression of BV (Cox et al., 2016). Verteramo and colleagues reported UP and MH as opportunistic pathogens of the lower female genital tract (Verteramo et al., 2009). However, The European STI guidelines do not recommend routine screening and treatment for these pathogens (Horner et al., 2018).

In this study, more than half of the study participants harboured multiple infections with sexually transmitted pathogens (52.7%). Multiple infections are reported to have a negative impact on the treatment of STIs and regarded as a risk factor for cervical cancer (Magaña Contreras et al., 2015). Of the multiple infections, the co-infection of UP/HR-HPV occurred at a rate of 21.3% women, similar to that reported among sexually active women attending the outpatient clinic for routine cervical cancer screening (Parthenis et al., 2018). Moreover, a study among reproductive-age women from Gambia reported that 50% of women with HPV infection were co-infected with UP (Bah Camara et al., 2018). Women with detectable UP are found to have high levels of inflammatory cytokines, a biological co-factor that may increase the probability of persistent HPV infection and development of precancerous lesions (Biernat-Sudolska et al., 2011; Lobao et al., 2017; Roeters et al., 2010). Similarly, the prevalence of UP was significantly 2-fold higher in women with high-grade squamous intraepithelial lesions (57.5%) compared to women with normal cytology (21.3%) (Farag et al., 2013). The interaction of HR-HPV with UP demonstrates the need to screen for these pathogens as they may play a significant role in initiating the development of cervical cancer lesions.

The significant association of viral STIs (HSV-2 & HIV infection) with HR-HPV infection has been previously observed in other studies (Li & Wen, 2017; Taku et al., 2020). HSV-2 increases the odds of acquiring other STIs (such as NG) and is considered as the significant co-factor for HPV in the development of cervical cancer (Li & Wen, 2017; Smith...
Women positive for HSV-2 and HIV infection were reported to have cervicovaginal inflammation and harbour a high diversity of microbes (Keller et al., 2019). These viral STIs have been found as independent risk factors of cervical cancer diseases. For example, a case-control study showed that HIV-positive women had a significantly increased prevalence of abnormal cytology (13.0%) compared to HIV-negative women (5.0%) (Suehiro et al., 2020). Similarly, the presence of HSV-2 infection was 5-fold higher in women with cervical intraepithelial neoplasia and squamous cell carcinoma compared to those with normal cervical cytology (Zhao et al., 2012). Moreover, the co-infection of HPV/HSV-2 was significantly associated with cervical cancer lesions and cervical cancer than healthy women suggesting that this co-infection could be involved in the progression of cervical cancer (Zhao et al., 2012). The findings highlight the need to consider awareness and educational programmes about the risk of these viruses in order to help reduce their outcome.

With South Africa having a high burden of STIs, particularly among asymptomatic women, an effective strategy to diagnose and treat STIs is needed. The high prevalence of HPV observed in this population confirms the need for HPV vaccination. Syndromic management policy has been reported to have low specificity and sensitivity in identifying the most common STIs, such as NG and CT (Maina, Kimani & Anzala, 2016; Marx et al., 2010). The syndromic management approach may not be good enough to control STIs when utilized alone as it results in a high STI prevalence of undiagnosed infections that may facilitate the transmission of HIV infection (Ward & Rönn, 2010). The high prevalence of STIs in this region encourages the need to implement diagnostic STI screening tests as the potential strategy to effectively decrease the burden of STI since the majority of STI-positive women are asymptomatic and remain untreated (Barnabas et al., 2018). The screening will be beneficial not only for asymptomatic women but for those with symptoms in the general population or high-risk populations and facilitate receipt of appropriate treatment. Furthermore, considering the high prevalence of HR-HPV observed in this population, STI screening would be of assistance as it will help to reduce the burden of sexually transmitted pathogens that could potentially promote the development of persistence and cervical cancer lesions (Yong, 2017).

We acknowledge that the study had some potential limitations including small sample size, thus the results of this study cannot be regarded as the representative sample for the whole population of rural Eastern Cape Province. Also, the study was designed for HPV screening and this may result to a potential sampling bias in the context of sexually transmitted infections. Furthermore, in this study we depended on self-reported questionnaire for some data such as vaginal discharge, frequency of vaginal discharge and sexual behaviour. Therefore, this information may also introduce bias during the collection of participant information and analysis.

CONCLUSION

A high prevalence of sexually transmitted pathogens, particularly TV, UP, and MH was documented in this rural community. HSV-2 and HIV were co-factors strongly
associated with HR-HPV infection. The high prevalence of these pathogens underscores the need to revise the syndromic management policy by implementing effective strategies of prevention, screening tests, and management for sexually transmitted pathogens. The study also highlights the need to encourage routine screening of STIs for all women screened for cervical cancer. The high prevalence of HPV emphasizes the ongoing need for HPV vaccination.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| STIs         | sexually transmitted infections |
| BV           | bacterial vaginosis |
| TP           | Treponema pallidum |
| CT           | Chlamydia trachomatis |
| HSV-2        | Herpes simplex virus-2 |
| MG           | Mycoplasma genitalium |
| MH           | Mycoplasma hominis |
| NG           | Neisseria gonorhoeae |
| TV           | Trichomonas vaginalis |
| UP           | Ureaplasma spp |
| HR-HPV       | high-risk human papillomavirus |

ACKNOWLEDGEMENTS

We thank the community clinic staff members, Sr Virginia Maqoga, Luvie Lutotswana, and the women who kindly participated in the study. Opinions, findings, and conclusions or recommendations are those of the authors alone and do not reflect National Research Foundation opinions.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by the National Research Foundation of South Africa (Grant Numbers: 64815), Poliomyelitis Research Foundation (PRF) and South African Medical Research Council- FORTE (SAMRC-FORTE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
National Research Foundation of South Africa: 64815.
Poliomyelitis Research Foundation (PRF).
South African Medical Research Council- FORTE (SAMRC-FORTE).

Competing Interests

The authors declare there are no competing interests.
Author Contributions

- Ongeziwe Taku conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Adrian Brink and Anna-Lise Williamson conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Tracy L. Meiring, Charles B. Businge and Zizipho Z.A. Mbulawa conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Keletso Phohlo performed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Human Research Ethics Committees of the University of Cape Town (UCT) (HREC reference 615/2017), Walter Sisulu University (reference 016/2017), and Eastern Cape Department of Health Ethics (EC reference 2017RP0_484) approved this research.

Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Other than the IRB at the University of Cape Town and Walter Sisulu University, permission was also obtained from the Eastern Cape Department of Health Ethics (EC reference 2017RP0_484).

Data Availability

The following information was supplied regarding data availability:

The raw data are available in the Supplemental Files.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10793#supplemental-information.

REFERENCES

Adachi K, Klausner JD, Bristow CC, Xu J, Ank B, Morgado MG, Watts DH, Weir F, Persing D, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Nielsen-Saines K. 2015. Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV transmission. Sexually Transmitted Diseases 42:554–565 DOI 10.1097/olq.0000000000000340.

Adefuye A, Sales K. 2012. Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) 2012:548150 DOI 10.6064/2012/548150.
Bah Camara H, Anyanwu M, Wright E, Kimmitt PT. 2018. Human papilloma virus genotype distribution and risk factor analysis amongst reproductive-age women in urban Gambia. *Journal of Medical Microbiology* 67:1645–1654 DOI 10.1099/jmm.0.000848.

Barnabas SL, Dabee S, Passmore JS, Jaspan HB, Lewis DA, Jaumdally SZ, Gamieldien H, Masson L, Muller E, Maseko VD, Mkhize N, Mbulawa Z, Williamson AL, Gray CM, Hope TJ, Chiodi F, Dietrich J, Gray G, Bekker LG. 2018. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. *International Journal of STD and AIDS* 29:531–539 DOI 10.1177/0956462417740487.

Barrientos-Durán A, De Salazar A, Alvarez-Estévez M, Fuentes-López A, Espadafor B, García F. 2020. Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit. *European Journal of Clinical Microbiology and Infectious Diseases* 39:235–241 DOI 10.1007/s10096-019-03686-w.

Biernat-Sudolska M, Szostek S, Rojek-Zakrzewska D, Klimek M, Kosz-Vnenchak M. 2011. Concomitant infections with human papillomavirus and various mycoplasma and ureaplasma species in women with abnormal cervical cytology. *Advances in Medical Sciences* 56:299–303 DOI 10.2478/v10039-011-0028-9.

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. 2010. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *Journal of Infectious Diseases* 202:1789–1799 DOI 10.1086/657321.

Cox C, Watt AP, McKenna JP, Coyle PV. 2016. Mycoplasma hominis and Gardnerella vaginalis display a significant synergistic relationship in bacterial vaginosis. *European Journal of Clinical Microbiology and Infectious Diseases* 35:481–487 DOI 10.1007/s10096-015-2564-x.

Cristillo AD, Bristow CC, Peeling R, Van Der Pol B, de Cortina SH, Dimov IK, Pai NP, Jin Shin D, Chiu RY, Klapperich C, Madhivanan P, Morris SR, Klausner JD. 2017. Point-of-care sexually transmitted infection diagnostics: proceedings of the STAR sexually transmitted infection-clinical trial group programmatic meeting. *Sexually Transmitted Diseases* 44:211–218 DOI 10.1097/OLQ.0000000000000572.

De Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira ÉC, Pereira MW, Carvalho MD, Pelloso SM, Bonini MG, Gimenes F, Consolaro ME. 2016. Association of human papillomavirus, Neisseria gonorrhoeae and *Chlamydia trachomatis* co-infections on the risk of high-grade squamous intraepithelial cervical lesion. *American Journal of Cancer Research* 6:1371–1383.

De Waaij DJ, Dubbink JH, Ouburg S, Peters RPH, Morre SA. 2017. Prevalence of Trichomonas vaginalis infection and protozoan load in South African women: a cross-sectional study. *BMJ Open* 7:e016959 DOI 10.1136/bmjopen-2017-016959.
Deluca GD, Basiletti J, Schelover E, Vásquez ND, Alonso JM, Marin HM, Lucero RH, Picconi MA. 2011. *Chlamydia trachomatis* as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. *The Brazilian Journal of Infectious Diseases* 15(6):567–572 DOI 10.1016/s1413-8670(11)70252-5.

Denny LA, Franceschi S, de San José S, Heard I, Moscicki AB, Palefsky J. 2012. Human papillomavirus, human immunodeficiency virus and immunosuppression. *Vaccine* 30(Suppl 5):F168–F174 DOI 10.1016/j.vaccine.2012.06.045.

Dubbink JH, Verweij SP, Struthers HE, Ouburg S, McIntyre JA, Morré SA, Peters RP. 2018. Genital *Chlamydia trachomatis* and Neisseria gonorrhoeae infections among women in sub-Saharan Africa: a structured review. *International Journal of STD and AIDS* 29:806–824 DOI 10.1177/0956462418758224.

Farag MAE, Morad AWA, Azzazi A, Fayed SM, Eldin AKZ. 2013. Association between genital mycoplasma and cervical squamous cell atypia. *Middle East Fertility Society Journal* 18(4):241–245.

Francis SC, Mthiyane TN, Baisley K, McHunu SL, Ferguson JB, Smit T, Crucitti T, Garea D, Dlamini S, Mutevedzi T, Seeley J, Pillay D, McGrath N, Shahmanesh M. 2018. Prevalence of sexually transmitted infections among young people in South Africa: a nested survey in a health and demographic surveillance site. *PLOS Medicine* 15:e1002512 DOI 10.1371/journal.pmed.1002512.

Health NDo. 2015. Sexually transmitted infections management guidelines, adapted from standard treatment guidelines and essential drugs list primary health care. In: Standard treatment guidelines and essential drugs list for primary healthcare, editor. Available at [http://www.kznhealth.gov.za/pharmacy/edlphc2014apdf](http://www.kznhealth.gov.za/pharmacy/edlphc2014apdf) (accessed on 4 May 2020).

Horner P, Donders G, Gusini M, Gomberg M, Jensen JS, Unemo M. 2018. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the European STI Guidelines Editorial Board. *Journal of the European Academy of Dermatology and Venereology* 32:1845–1851 DOI 10.1111/jdv.15146.

Jensen KE, Thomsen LT, Schmiedel S, Frederiksen K, Norrild B, van den Brule A, Iftner T, Kjaer SK. 2014. *Chlamydia trachomatis* and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. *Sexually Transmitted Infections* 90:550–555 DOI 10.1136/sti-2013-051431.

Johnson LF, Lewis DA. 2008. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. *Sexually Transmitted Diseases* 35:946–959 DOI 10.1097/OLQ.0b013e3181812d15.

Joseph Davey DL, Nyemba DC, Gomba Y, Bekker LG, Taleghani S, DiTullio DJ, Shabsovich D, Gorbach PM, Coates TJ, Klausner JD, Myer L. 2019. Prevalence and correlates of sexually transmitted infections in pregnancy in HIV-infected and- uninfected women in Cape Town, South Africa. *PLOS ONE* 14:e0218349 DOI 10.1371/journal.pone.0218349.
Kaambo E, Africa C, Chambuso R, Passmore JS. 2018. Vaginal Microbiomes Associated With Aerobic Vaginitis and Bacterial Vaginosis. *Frontiers in Public Health* 6:1–6 DOI 10.3389/fpubh.2018.00078.

Keller MJ, Huber A, Espinoza L, Serrano MG, Parikh HI, Buck GA, Gold JA, Wu Y, Wang T, Herold BC. 2019. Impact of herpes simplex virus Type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome. *Journal of Infectious Diseases* 220:852–861 DOI 10.1093/infdis/jiz203.

Kissinger P. 2015. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. *BMC Infectious Diseases* 15:307 DOI 10.1186/s12879-015-1055-0.

Kularatne RS, Niit R, Rowley J, Kufa-Chakezha T, Peters RPH, Taylor MM, Johnson LF, Korenromp EL. 2018. Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: Estimates using the Spectrum-STI model, 1990-2017. *PLOS ONE* 13:e0205863 DOI 10.1371/journal.pone.0205863.

Lee V, Tobin JM, Foley E. 2006. Relationship of cervical ectopy to chlamydia infection in young women. *Journal of Family Planning and Reproductive Health Care* 32:104–106 DOI 10.1783/147118906776276440.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J, Future I, Group IIS. 2011. *Chlamydia trachomatis* infection and risk of cervical intraepithelial neoplasia. *Sexually Transmitted Infections* 87:372–376 DOI 10.1136/sti.2010.044354.

Li S, Wen X. 2017. Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999-2014). *BMC Cancer* 17:726 DOI 10.1186/s12885-017-3734-2.

Liu J, Liu W, Liu Y, Zhou X, Zhang Z, Sun Z. 2016. Prevalence of microorganisms co-infections in human papillomaviruses infected women in Northern China. *Archives of Gynecology and Obstetrics* 293:595–602 DOI 10.1007/s00404-015-3826-7.

Lobao TN, Campos GB, Selis NN, Amorim AT, Souza SG, Mafra SS, Pereira LS, Santos DBDOS, Figueiredo TB, Marques LM, Timenetsky J. 2017. Ureaplasma urealyticum and U. parvum in sexually active women attending public health clinics in Brazil. *Epidemiology and Infection* 145:2341–2351 DOI 10.1017/S0950268817001145.

Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, Boily MC. 2017. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. *The Lancet Infectious Diseases* 17:1303–1316 DOI 10.1016/s1473-3099(17)30405-x.

Magaña Contreras M, Contreras-Paredes A, Chavez-Blanco A, Lizano M, De la Cruz-Hernandez Y, De la Cruz-Hernandez E. 2015. Prevalence of sexually transmitted pathogens associated with HPV infection in cervical samples in a Mexican population. *Journal of Medical Virology* 87:2098–2105 DOI 10.1002/jmv.24278.

Maina AN, Kimani J, Anzala O. 2016. Prevalence and risk factors of three curable sexually transmitted infections among women in Nairobi, Kenya. *BMC Research Notes* 9:193 DOI 10.1186/s13104-016-1990-x.
Marovt M, Kese D, Kotar T, Knet N, Miljkovic J, Soba B, Maticic M. 2015. Ureaplasma parvum and Ureaplasma urealyticum detected with the same frequency among women with and without symptoms of urogenital tract infection. *European Journal of Clinical Microbiology and Infectious Diseases* **34**:1237–1245 DOI 10.1007/s10096-015-2351-8.

Marx G, John-Stewart G, Bosire R, Wamalwa D, Otieno P, Farquhar C. 2010. Diagnosis of sexually transmitted infections and bacterial vaginosis among HIV-1-infected pregnant women in Nairobi. *International Journal of STD and AIDS* **21**:549–552 DOI 10.1258/ijsa.2010.010005.

Mayaud P, Mabey D. 2004. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. *Sexually Transmitted Infections* **80**:174–182 DOI 10.1136/sti.2002.004101.

Mbulawa ZZA, Van Schalkwyk C, Hu NC, Meiring TL, Barnabas S, Dabee S, Jaspan H, Kriek JM, Jaumdally SZ, Muller E, Bekker LG, Lewis DA, Dietrich J, Gray G, Passmore JS, Williamson AL. 2018. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. *PLOS ONE* **13**:e0190166 DOI 10.1371/journal.pone.0190166.

Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schimvander Loeff MF, vander Laan LE, Kipping S, Taylor D, Giuliano AR. 2018. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial. *Sexually Transmitted Infections* **94**:55–61 DOI 10.1136/sextrans-2016-053046.

Mermelstein S, Plax K. 2016. Sexually transmitted infections. *Current Treatment Options in Pediatrics* **2**:156–170 DOI 10.1007/s40746-016-0058-4.

Moodley D, Moodley P, Sebitloane M, Soowamber D, McNaughton-Reyes HL, Groves AK, Maman S. 2015. High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in KwaZulu Natal, South Africa. *Sexually Transmitted Diseases* **42**:43–47 DOI 10.1097/OLQ.0000000000000219.

Mudau M, Peters RP, De Vos L, Olivier DH, JD D, Mkwanazi ES, McIntyre JA, Klausner JD, Medina-Marino A. 2018. High prevalence of asymptomatic sexually transmitted infections among human immunodeficiency virus-infected pregnant women in a low-income South African community. *International Journal of STD and AIDS* **29**:324–333 DOI 10.1177/0956462417724908.

Naidoo S, Wand H, Abbai NS, Ramjee G. 2014. High prevalence and incidence of sexually transmitted infections among women living in KwaZulu-Natal, South Africa. *AIDS Research and Therapy* **11**(1):1–7 DOI 10.1186/1742-6405-11-31.

Paba P, Bonifacio D, Di Bonito L, Ombres D, Favalli C, Syrjänen K, Ciotti M. 2008. Co-expression of HSV2 and *Chlamydia trachomatis* in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. *Intervirology* **51**:230–234 DOI 10.1159/000156481.

Parthenis C, Panagopoulos P, Margari N, Kottaridi C, Spathis A, Pouliakis A, Konstantoudakis S, Chrelias G, Chrelias C, Papantoniou N, Panayiotides IG, Tsiodras S. 2018. The association between sexually transmitted infections, human
papillomavirus, and cervical cytology abnormalities among women in Greece. *International Journal of Infectious Diseases* 73:72–77 DOI 10.1016/j.ijid.2018.06.001.

**Poole DN, McClelland RS. 2013.** Global epidemiology of Trichomonas vaginalis. *Sexually Transmitted Infections* 89:418–422 DOI 10.1136/sextrans-2013-051075.

**Roeters AM, Boon ME, Haafken Mvan, Vernooij F, Bontekoe TR, Heintz AP. 2010.** Inflammatory events as detected in cervical smears and squamous intraepithelial lesions. *Diagnostic Cytopathology* 38:85–93 DOI 10.1002/dc.21169.

**Rumyantseva T, Khayrullina G, Guschin A, Donders G. 2019.** Prevalence of Ureaplasma spp. and Mycoplasma hominis in healthy women and patients with flora alterations. *Diagnostic Microbiology and Infectious Disease* 93:227–231 DOI 10.1016/j.diagmicrobio.2018.10.001.

**Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. 2011.** Human papillomavirus testing in the prevention of cervical cancer. *Journal of the National Cancer Institute* 103:368–383 DOI 10.1093/jnci/djq562.

**Sha BE, Chen HY, Wang QJ, Zariiffard MR, Cohen MH, Spear GT. 2005.** Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus–infected women. *Journal of Clinical Microbiology* 43:4607–4612 DOI 10.1128/JCM.43.9.4607-4612.2005.

**Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Rylander E. 2005.** *Chlamydia trachomatis* infection and persistence of human papillomavirus. *International Journal of Cancer* 116:110–115 DOI 10.1002/ijc.20970.

**Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J, Castellsagué X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R. 2002a.** Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *Journal of the National Cancer Institute* 94:1604–1613 DOI 10.1093/jnci/94.21.1604.

**Smith JS, Muñoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S, Bosch FX, Walboomers JM, Peeling RW. 2002b.** Evidence for *Chlamydia trachomatis* as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *Journal of Infectious Diseases* 185:324–331 DOI 10.1086/338569.

**Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, Da Costa M, Moscicki AB, Palefsky JM, Makunike-Mutasa R, Chipato T, van der Straten A, Sawaya GF. 2010.** Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. *PLOS ONE* 5:e10094 DOI 10.1371/journal.pone.0010094.

**Suehiro TT, Damke GMZF, Damke E, de Azevedo Ramos PLR, de Andrade Pereira Silva M, Pelloso SM, Huh WK, Franco RAF, Da Silva VRS, Scarinci IC, Consolaro MEL. 2020.** Cervical and oral human papillomavirus infection in women living with human immunodeficiency virus (HIV) and matched HIV-negative controls in Brazil. *Infectious Agents and Cancer* 15:1–11 DOI 10.1186/s13027-020-00301-y.
Sznitman SR, Carey MP, Vanable PA, DiClemente RJ, Brown LK, Valois RF, Hennessy M, Farber N, Rizzo C, Caliendo A, Salazar LF, Stanton BF, Romer D. 2010. The impact of community-based sexually transmitted infection screening results on sexual risk behaviors of African American adolescents. *Journal of Adolescent Health* 47:12–19 DOI 10.1016/j.jadohealth.2009.12.024.

Taku O, Businge CB, Mdaka ML, Phohlo K, Basera W, Garcia-Jardon M, Meiring TL, Gyllensten U, Williamson AL, Mbulawa ZZA. 2020. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa. *International Journal of Infectious Diseases* 95:176–182 DOI 10.1016/j.ijid.2020.02.051.

Van der Pol B. 2007. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. *Clinical Infectious Diseases* 44:23–25 DOI 10.1086/509934.

Venkatesh KK, van der Straten A, Mayer KH, Blanchard K, Ramjee G, Lurie MN, Chipato T, Padian NS, De Bruyn G. 2011. African women recently infected with HIV-1 and HSV-2 have increased risk of acquiring Neisseria gonorrhoeae and *Chlamydia trachomatis* in the Methods for Improving Reproductive Health in Africa trial. *Sexually Transmitted Diseases* 38:562–570 DOI 10.1097/OLQ.0b013e31820a8c2.

Verteramo R, Pierangeli A, Mancini E, Calzolari E, Buccì M, Osborn J, Nicosia R, Chiarini F, Antonelli G, Degener AM. 2009. Human Papillomaviruses and genital co-infections in gynaecological outpatients. *BMC Infectious Diseases* 9:16 DOI 10.1186/1471-2334-9-16.

Vriend HJ, Bogaards JA, van Bergen JE, Brink AA, van den Broek IV, Høebe CJ, King AJ, van der Sande MA, Wolffs PF, De Melker HE, The Medical Microbiological Laboratories and the CSI group. 2015. Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without *Chlamydia trachomatis* co-infection. *Cancer Medicine* 4:1589–1598 DOI 10.1002/cam4.496.

Waites KB, Katz B, Schelonka RL. 2005. Mycoplasmas and ureaplasmas as neonatal pathogens. *Clinical Microbiology Reviews* 18:757–789 DOI 10.1128/CMR.18.4.757-789.2005.

Ward H, Rönn M. 2010. Contribution of sexually transmitted infections to the sexual transmission of HIV. *Current Opinion in HIV and AIDS* 5:305–310 DOI 10.1097/COH.0b013e32833a8844.

WHO. 2018. Report on global sexually transmitted infection surveillance. Available at https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/ (accessed on 1 May 2020).

Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, Kiarie J, Santesso N, Unemo M. 2019. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. *Journal of the International AIDS Society* 22(Suppl 6):e25343 DOI 10.1002/jia2.25343.
Wilkinson D, Abdool Karim SS, Harrison A, Lurie M, Colvin M, Connolly C, Sturm AW. 1999. Unrecognized sexually transmitted infections in rural South African women: a hidden epidemic. *Bulletin of the World Health Organization* 77:22–28.

Yong J. 2017. Co-infections with human papillomavirus and mycoplasma/ureaplasma spp. in women with abnormal cervical cytology. *Research and Reports in Gynecology and Obstetrics* 1(1):1–3.

Zhao Y, Cao X, Zheng Y, Tang J, Cai W, Wang H, Gao Y, Wang Y. 2012. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. *Journal of Medical Virology* 84:1920–1927 DOI 10.1002/jmv.23353.